1 / 13

BSRBR-RA UK CRN ID: 7302

BSRBR-RA UK CRN ID: 7302. August 2013 update. Recruitment . Numbers recruited up to 25/07/2013. Certolizumab. 605 As of 25/07/2013. Must have diagnosis of RA. Must be registered within 6 months of first dose of certolizumab. Can be re-registered if already on the study. Tocilizumab.

ozzie
Download Presentation

BSRBR-RA UK CRN ID: 7302

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BSRBR-RAUK CRN ID: 7302 August 2013 update

  2. Recruitment Numbers recruited up to 25/07/2013 Certolizumab 605 As of 25/07/2013 Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab Can be re-registered if already on the study Tocilizumab 492 As of 25/07//2013 Must have diagnosis of RA Must be registered within 6 months of first dose of tocilizumab Can be re-registered if already on the study Anti-TNF Comparison Cohort 561 As of 25/07//2013 Must have diagnosis of RA Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab

  3. Recruitment 40 20 Certolizumab recruitment by month 0 July 2011 July 2013 40 Tocilizumab recruitment by month 20 0 July 2013 July 2011 60 Anti-TNF cohort recruitment by month 30 0 Dec2011 July 2013

  4. Recruitment 01/01/2013 – 19/07/2013

  5. BSR Region Awards January - July 2013 North West Yorkshire and the Humber East Midlands 90 89 85

  6. Help is available with the BSRBR-RA If you do not have enough staff support currently, then in England the National Institute for Health Research Comprehensive Clinical Research Network (CCRN) may be able to provide assistance What is the CCRN? The CCRN is made up of 25 Comprehensive Local Research Networks (CLRNs) which cover the whole of England. Each local Network facilitates research within their region, with the aim of widening participation in research. A study is eligible for CLRN assistance if it has been adopted on to the Network portfolio of studies; the BSRBR-RA was adopted on to this portfolio in 2008 (ID: 7302). How can my CLRN help me? The CLRN may be able to help by assisting in R&D set up or by providing funding for the people/facilities you require in order to carry out research in which you are involved in. For example, you may be allocated research nurse time or a data clerk to assist with the recruitment and follow up of participants on the BSRBR-RA. How can I apply for CLRN help? You should contact the team within your regional network (details found via the link below) to discuss your requirements. You will then have to complete an application form, with which we can help. www.crncc.nihr.ac.uk/about_us/ccrn/ccrn_about_us/clrns_list.htm The BSRBR-RA Study reference number within the Network is 7302 – please remember to quote this when asking for help with the study. If you need any help with completing the paperwork, please contact katy.mowbray@manchester.ac.uk

  7. Is there help outside of England? Regional Support Northern Ireland Scotland Wales The Northern Ireland Clinical Research Network (NICRN) may be able to provide assistance in Northern Ireland in the same way as the NIHR CCRN in England, please contact the team to discuss requirements: NHS Scotland may be able to provide assistance in Scotland in the same way as the NIHR CCRN in England, please contact the team to discuss if support is possible for you: The National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC) may be able to provide assistance in Wales in the same way as the NIHR CCRN in England , please contact the team to discuss requirements: info.NICRN@belfasttrust.hscni.net http://nrs.mtcserver8.com/297_ClinicalResearchNetworks.html nischr-crc@wales.nhs.uk

  8. Recent BSRBR-RA publications • Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Mercer, L., Davies, R., Galloway, J., Low, A., Lunt, M., Dixon, W., Watson, K., Symmons, D., Hyrich, K. & BSRBR_Control_Centre Consortium, B (2013). Rheumatology (Oxford), 52(1), 91-98. • Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Mercer, L., Low, A., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K. & BSRBR_Control_Centre_Consortium, B (2013). Ann Rheum Dis, 72(1), 143-144. • The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & , B (2013). Ann Rheum Dis, [Epub ahead of print]

  9. Accessing BSRBR-RA data http://www.rheumatology.org.uk/resources/bsr_biologics_registers/requesting_data_from_bsrbr.aspx

  10. Recent/ongoing research projects via the BSRBR-RA data access scheme • Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA • Study of fatigue in inflammatory arthritis • Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D • To explore the influence of gender and gender-related variables on severity of prognosis for RA • Obesity and clinical response to anti-TNF medication

  11. 2) ACR conference 2013 – San Diego BSRBR-RA abstracts submitted: • 1. Non-differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. 2. Comparison of the Occurrence and Severity of Myocardial Infarction in Subjects with Rheumatoid Arthritis Receiving Tumour Necrosis Factor Inhibitors or Standard Non-biologic Disease Modifying Anti-rheumatic Drugs: Results from a Linkage between the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. 3. The risk of serious infections in patients receiving rituximab for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.

  12. What to look out for soon 1) Web portal development • The Robertson Centre at the University of Glasgow are developing a new web portal for online data capture. • The portal will include the facility to register new patients as well as enter follow-up data for patients already on the study

  13. Acknowledgements • UK Consultant Rheumatologists and Specialist Nurses • Comprehensive Local Research Networks • BSRBR Control Centre Consortium • British Society for Rheumatology • Arthritis Research UK Epidemiology Unit, Manchester

More Related